drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
A HER2-targeted antibody–drug conjugate composed of trastuzumab linked via a cleavable linker to the topoisomerase I inhibitor payload deruxtecan (DXd); binds HER2 (ERBB2), is internalized, and releases DXd to inhibit topo I and induce DNA damage/apoptosis, with potential bystander effect and Fc-mediated ADCC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Trastuzumab Deruxtecan
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER2-targeted ADC: trastuzumab binds HER2 (ERBB2), is internalized, and via a cleavable linker releases the topoisomerase I inhibitor deruxtecan (DXd) in lysosomes, causing DNA damage and apoptosis; the membrane-permeable payload enables a bystander effect, and the antibody Fc can mediate ADCC.
drug_name
Trastuzumab deruxtecan (T-DXd)
nct_id_drug_ref
NCT06058988